Profile
Michael Khan is currently the Chief Executive Officer at Argonaute RNA Ltd. He is also a Member at Diabetes UK and HEART UK.
Previously, he served as the Executive Director & Chief Medical Officer at Silence Therapeutics Plc from 2013 to 2016.
He also held the position of Head-Molecular Medicine & Associate Professor at the University of Warwick.
Dr. Khan holds a doctorate degree from University College London.
Michael Khan active positions
| Companies | Position | Start |
|---|---|---|
HEART UK | Corporate Officer/Principal | - |
Diabetes UK | Corporate Officer/Principal | - |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Develops safe and reliable methods of temporarily silencing target genes in different tissue cells | Chief Executive Officer | 01/01/2021 |
Former positions of Michael Khan
| Companies | Position | End |
|---|---|---|
| SILENCE THERAPEUTICS PLC | Chief Tech/Sci/R&D Officer | 17/06/2016 |
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Training of Michael Khan
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Silence Therapeutics Plc
Silence Therapeutics Plc Miscellaneous Commercial ServicesCommercial Services Engages in the research and development of novel pharmaceutical products | Commercial Services |
University of Warwick
University of Warwick Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University College London
University College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Diabetes UK | |
HEART UK | |
Argonaute RNA Ltd.
Argonaute RNA Ltd. Miscellaneous Commercial ServicesCommercial Services Develops safe and reliable methods of temporarily silencing target genes in different tissue cells | Commercial Services |
- Stock Market
- Insiders
- Michael Khan
















